Zydus Begins Human Trials For Potential COVID-19 Vaccine
Jul 15, 2020 | Pratirodh Bureau
Vaccine-maker Bharat Biotech claimed that with several hundred million doses administered worldwide, Covaxin has demonstrated an excellent safety record with minimal adverse events and no vaccine associated cases detected for myocarditis or thrombocytopenia
Indian pharmaceutical company Zydus said on Wednesday it has started human studies for its potential COVID-19 vaccine, as coronavirus infections continue to surge in the world’s third worst-hit nation.
ZyCoV-D, its plasmid DNA vaccine, was found to be safe, immunogenic and well-tolerated in the pre-clinical toxicity studies, Zydus said.
In the human trials, Zydus will enrol over 1,000 subjects across multiple clinical study sites in India.